Clinical Research Directory
Browse clinical research sites, groups, and studies.
Vivatlac in Irritable Bowel Syndrome II (ViIBS2)
Sponsor: The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
Summary
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients
Official title: Effects of Vivatlac Synbiotic in Patients With Irritable Bowel Syndrome - A Randomized, Double-blind, Placebo-Controlled, 36 Weeks Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-11-21
Completion Date
2027-12
Last Updated
2025-12-15
Healthy Volunteers
No
Conditions
Interventions
Vivatlac Synbiotic
Vivatlac Synbiotic containing a total of 4.5 x 10\^9 colony forming units (CFU) of nine different probiotic bacteria. Probiotic bacteria strains and their CFU amount per capsule are: Lactococcus lactis Ll-23, 9.00 x 10\^8 CFU; Lactobacillus helveticus SP 27, 9.00 x 10\^8 CFU; Bifidobacterium longum Bl-05, 6.75 x 10\^8 CFU; Bifidobacterium longum ES1, 4.50 x 10\^8 CFU; Lacticaseibacillus rhamnosus Lr-32, 4.50 x 10\^8 CFU; Streptococcus thermophiles St-21, 4.50 x 10\^8 CFU; Lacticaseibacillus casei Lc-11, 2.25 x 10\^8 CFU; Lactiplantibacillus plantarum Lp-115, 2.25 x 10\^8 CFU; Bifidobacterium bifidum Bb-02, 2.25 x 10\^8 CFU. As a prebiotic component each capsule contains 63 mg of fructooligosaccharides.
Placebo
Capsule containing maize starch with identical appearance as verum.
Locations (3)
District Hospital Jarocin
Jarocin, Poland
GP Clinic Spitalna
Jarocin, Poland
GP Clinic Wroclawska
Jarocin, Poland